David Sinclair to test rejuvenation drugs in $101 million XPrize competition
David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
MIT Tech Review
Summary
Longevity scientist David Sinclair plans to launch human trials of an oral "reprogramming" drug as part of a $101 million competition. The effort aims to develop treatments that could make people biologically younger.